Cargando…

Clinical impact of remnant lymphatic invasion on the recurrence of esophageal squamous cell carcinoma after esophagectomy with neoadjuvant chemotherapy

For stage II and III esophageal squamous cell carcinoma (ESCC), neoadjuvant chemotherapy (NAC) followed by esophagectomy is recommended in the Japanese guidelines for the diagnosis and treatment of esophageal cancer. However, recurrence of ESCC is common regardless of the NAC regimen and surgical me...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuda, Sho, Ohuchida, Kenoki, Shindo, Koji, Moriyama, Taiki, Kawata, Jun, Tamura, Koji, Sada, Masafumi, Nagayoshi, Kinuko, Mizuuchi, Yusuke, Ikenaga, Naoki, Nakata, Kohei, Oda, Yoshinao, Nakamura, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404688/
https://www.ncbi.nlm.nih.gov/pubmed/36039060
http://dx.doi.org/10.3892/ol.2022.13457
_version_ 1784773693889576960
author Okuda, Sho
Ohuchida, Kenoki
Shindo, Koji
Moriyama, Taiki
Kawata, Jun
Tamura, Koji
Sada, Masafumi
Nagayoshi, Kinuko
Mizuuchi, Yusuke
Ikenaga, Naoki
Nakata, Kohei
Oda, Yoshinao
Nakamura, Masafumi
author_facet Okuda, Sho
Ohuchida, Kenoki
Shindo, Koji
Moriyama, Taiki
Kawata, Jun
Tamura, Koji
Sada, Masafumi
Nagayoshi, Kinuko
Mizuuchi, Yusuke
Ikenaga, Naoki
Nakata, Kohei
Oda, Yoshinao
Nakamura, Masafumi
author_sort Okuda, Sho
collection PubMed
description For stage II and III esophageal squamous cell carcinoma (ESCC), neoadjuvant chemotherapy (NAC) followed by esophagectomy is recommended in the Japanese guidelines for the diagnosis and treatment of esophageal cancer. However, recurrence of ESCC is common regardless of the NAC regimen and surgical method, and NAC demonstrates limited efficacy against recurrence. Therefore, the present study was conducted to identify risk factors of recurrence of ESCC with surgery after NAC. The outcomes of 51 patients who underwent esophagectomy for ESCC after NAC from 2010 to 2017 at Kyushu University Hospital were retrospectively analyzed. A total of 52 patients with ESCC without NAC followed by esophagectomy from 2001 to 2017 were selected for comparison. Among patients who underwent NAC followed by surgery, only lymphatic invasion (LY; hazard ratio, 2.761; 95% CI, 1.86-6.43, P=0.018) was an independent factor significantly associated with 3-year recurrence-free survival in the multivariate analysis. In patients with pathologic lymph node metastasis (pN) and no LY after NAC, there was significantly less recurrence compared with patients with pN and LY (P=0.0085), whereas in patients without LY after NAC, the presence of pN was not significantly associated with recurrence (P=0.2401). There were significantly fewer LY (+) patients in the NAC (+) group (P=0.0158) compared with those in the NAC (−) group. The presence of LY was an independent risk factor for recurrence of ESCC after esophagectomy following NAC. Overall, adjuvant treatment after surgery may be required in cases with remnant LY after NAC.
format Online
Article
Text
id pubmed-9404688
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-94046882022-08-28 Clinical impact of remnant lymphatic invasion on the recurrence of esophageal squamous cell carcinoma after esophagectomy with neoadjuvant chemotherapy Okuda, Sho Ohuchida, Kenoki Shindo, Koji Moriyama, Taiki Kawata, Jun Tamura, Koji Sada, Masafumi Nagayoshi, Kinuko Mizuuchi, Yusuke Ikenaga, Naoki Nakata, Kohei Oda, Yoshinao Nakamura, Masafumi Oncol Lett Articles For stage II and III esophageal squamous cell carcinoma (ESCC), neoadjuvant chemotherapy (NAC) followed by esophagectomy is recommended in the Japanese guidelines for the diagnosis and treatment of esophageal cancer. However, recurrence of ESCC is common regardless of the NAC regimen and surgical method, and NAC demonstrates limited efficacy against recurrence. Therefore, the present study was conducted to identify risk factors of recurrence of ESCC with surgery after NAC. The outcomes of 51 patients who underwent esophagectomy for ESCC after NAC from 2010 to 2017 at Kyushu University Hospital were retrospectively analyzed. A total of 52 patients with ESCC without NAC followed by esophagectomy from 2001 to 2017 were selected for comparison. Among patients who underwent NAC followed by surgery, only lymphatic invasion (LY; hazard ratio, 2.761; 95% CI, 1.86-6.43, P=0.018) was an independent factor significantly associated with 3-year recurrence-free survival in the multivariate analysis. In patients with pathologic lymph node metastasis (pN) and no LY after NAC, there was significantly less recurrence compared with patients with pN and LY (P=0.0085), whereas in patients without LY after NAC, the presence of pN was not significantly associated with recurrence (P=0.2401). There were significantly fewer LY (+) patients in the NAC (+) group (P=0.0158) compared with those in the NAC (−) group. The presence of LY was an independent risk factor for recurrence of ESCC after esophagectomy following NAC. Overall, adjuvant treatment after surgery may be required in cases with remnant LY after NAC. D.A. Spandidos 2022-08-11 /pmc/articles/PMC9404688/ /pubmed/36039060 http://dx.doi.org/10.3892/ol.2022.13457 Text en Copyright: © Okuda et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Okuda, Sho
Ohuchida, Kenoki
Shindo, Koji
Moriyama, Taiki
Kawata, Jun
Tamura, Koji
Sada, Masafumi
Nagayoshi, Kinuko
Mizuuchi, Yusuke
Ikenaga, Naoki
Nakata, Kohei
Oda, Yoshinao
Nakamura, Masafumi
Clinical impact of remnant lymphatic invasion on the recurrence of esophageal squamous cell carcinoma after esophagectomy with neoadjuvant chemotherapy
title Clinical impact of remnant lymphatic invasion on the recurrence of esophageal squamous cell carcinoma after esophagectomy with neoadjuvant chemotherapy
title_full Clinical impact of remnant lymphatic invasion on the recurrence of esophageal squamous cell carcinoma after esophagectomy with neoadjuvant chemotherapy
title_fullStr Clinical impact of remnant lymphatic invasion on the recurrence of esophageal squamous cell carcinoma after esophagectomy with neoadjuvant chemotherapy
title_full_unstemmed Clinical impact of remnant lymphatic invasion on the recurrence of esophageal squamous cell carcinoma after esophagectomy with neoadjuvant chemotherapy
title_short Clinical impact of remnant lymphatic invasion on the recurrence of esophageal squamous cell carcinoma after esophagectomy with neoadjuvant chemotherapy
title_sort clinical impact of remnant lymphatic invasion on the recurrence of esophageal squamous cell carcinoma after esophagectomy with neoadjuvant chemotherapy
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404688/
https://www.ncbi.nlm.nih.gov/pubmed/36039060
http://dx.doi.org/10.3892/ol.2022.13457
work_keys_str_mv AT okudasho clinicalimpactofremnantlymphaticinvasionontherecurrenceofesophagealsquamouscellcarcinomaafteresophagectomywithneoadjuvantchemotherapy
AT ohuchidakenoki clinicalimpactofremnantlymphaticinvasionontherecurrenceofesophagealsquamouscellcarcinomaafteresophagectomywithneoadjuvantchemotherapy
AT shindokoji clinicalimpactofremnantlymphaticinvasionontherecurrenceofesophagealsquamouscellcarcinomaafteresophagectomywithneoadjuvantchemotherapy
AT moriyamataiki clinicalimpactofremnantlymphaticinvasionontherecurrenceofesophagealsquamouscellcarcinomaafteresophagectomywithneoadjuvantchemotherapy
AT kawatajun clinicalimpactofremnantlymphaticinvasionontherecurrenceofesophagealsquamouscellcarcinomaafteresophagectomywithneoadjuvantchemotherapy
AT tamurakoji clinicalimpactofremnantlymphaticinvasionontherecurrenceofesophagealsquamouscellcarcinomaafteresophagectomywithneoadjuvantchemotherapy
AT sadamasafumi clinicalimpactofremnantlymphaticinvasionontherecurrenceofesophagealsquamouscellcarcinomaafteresophagectomywithneoadjuvantchemotherapy
AT nagayoshikinuko clinicalimpactofremnantlymphaticinvasionontherecurrenceofesophagealsquamouscellcarcinomaafteresophagectomywithneoadjuvantchemotherapy
AT mizuuchiyusuke clinicalimpactofremnantlymphaticinvasionontherecurrenceofesophagealsquamouscellcarcinomaafteresophagectomywithneoadjuvantchemotherapy
AT ikenaganaoki clinicalimpactofremnantlymphaticinvasionontherecurrenceofesophagealsquamouscellcarcinomaafteresophagectomywithneoadjuvantchemotherapy
AT nakatakohei clinicalimpactofremnantlymphaticinvasionontherecurrenceofesophagealsquamouscellcarcinomaafteresophagectomywithneoadjuvantchemotherapy
AT odayoshinao clinicalimpactofremnantlymphaticinvasionontherecurrenceofesophagealsquamouscellcarcinomaafteresophagectomywithneoadjuvantchemotherapy
AT nakamuramasafumi clinicalimpactofremnantlymphaticinvasionontherecurrenceofesophagealsquamouscellcarcinomaafteresophagectomywithneoadjuvantchemotherapy